company background image
ACER logo

Acer Therapeutics OTCPK:ACER Stock Report

Last Price

US$0.80

Market Cap

US$19.7m

7D

-5.4%

1Y

-30.0%

Updated

20 Nov, 2023

Data

Company Financials +

Acer Therapeutics Inc.

OTCPK:ACER Stock Report

Market Cap: US$19.7m

ACER Stock Overview

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases.

ACER fundamental analysis
Snowflake Score
Valuation0/6
Future Growth5/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Acer Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acer Therapeutics
Historical stock prices
Current Share PriceUS$0.80
52 Week HighUS$4.56
52 Week LowUS$0.55
Beta0.44
1 Month Change-2.73%
3 Month Change21.88%
1 Year Change-30.04%
3 Year Change-70.42%
5 Year Change-96.75%
Change since IPO-91.99%

Recent News & Updates

Recent updates

Acer Therapeutics to develop ACER-801 for post-traumatic stress disorder treatment

Oct 05

Acer, Relief's metabolic disorder therapy ACER-001 gets orphan drug status in EU

Aug 12

FDA accepts Acer's resubmitted U.S. marketing application for urea cycle disorder therapy

Jul 28

Acer resubmits U.S. marketing application for urea cycle disorder therapy

Jul 18

Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

Feb 11
Companies Like Acer Therapeutics (NASDAQ:ACER) Can Afford To Invest In Growth

Acer Therapeutics: Deriving Value By Developing Therapies For Rare Diseases

Aug 31

We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

May 20
We're Not Very Worried About Acer Therapeutics' (NASDAQ:ACER) Cash Burn Rate

Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Feb 25
Need To Know: Acer Therapeutics Inc. (NASDAQ:ACER) Insiders Have Been Buying Shares

Acer Therapeutics completes enrollment in ACER-001 bioequivalence trial for urea cycle disorders

Dec 22

Shareholder Returns

ACERUS PharmaceuticalsUS Market
7D-5.4%1.2%0.4%
1Y-30.0%25.8%28.8%

Return vs Industry: ACER underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.

Return vs Market: ACER underperformed the US Market which returned 15.2% over the past year.

Price Volatility

Is ACER's price volatile compared to industry and market?
ACER volatility
ACER Average Weekly Movement32.3%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ACER's share price has been volatile over the past 3 months.

Volatility Over Time: ACER's weekly volatility has increased from 23% to 32% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199130Chris Schellinghttps://www.acertx.com

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company’s pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder.

Acer Therapeutics Inc. Fundamentals Summary

How do Acer Therapeutics's earnings and revenue compare to its market cap?
ACER fundamental statistics
Market capUS$19.68m
Earnings (TTM)-US$38.76m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACER income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$38.76m
Earnings-US$38.76m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio-96.4%

How did ACER perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.